Table 1. The clinicopathological characteristics of the pCR and non-pCR patients.

Characteristics	pCR (n=20)	Non-pCR (n=54)	t/χ2	P value
Age (years)	52.20±9.22	52.02±10.09	0.07	0.944
Tumor location			0.058	0.810
Left breast	9 [45]	26 [48]
Right breast	11 [55]	28 [52]
Clinical T stage			2.532	0.459
T1	3 [15]	7 [13]
T2	13 [65]	36 [67]
T3	4 [20]	6 [11]
T4	0	5 [9]
Clinical N stage			1.352	0.298
N0	6 [30]	11 [20]
N1	11 [55]	31 [57]
N2	3 [15]	9 [17]
N3	0	3 [6]
Histological type			3.954	0.055
IDC	19 [95]	40 [74]
Other types	1 [5]	14 [26]
Histological grade			0.458	0.795
1	2 [10]	3 [6]
2	12 [60]	34 [63]
3	6 [30]	17 [31]
ER			0.598	0.439
Negative	9 [45]	19 [35]
Positive	11 [55]	35 [65]
PR			0.094	0.759
Negative	13 [65]	33 [61]
Positive	7 [35]	21 [39]
HER2			9.004	0.003
Negative	4 [20]	32 [59]
Positive	16 [80]	22 [41]
Ki67			0.175	0.675
≤30%	6 [30]	19 [35]
>30%	14 [70]	35 [65]
Molecular subtype			9.195	0.020
Luminal A	1 [5]	6 [11]
Luminal B	1 [5]	17 [31]
HER2	15 [75]	20 [37]
TNBC	3 [15]	11 [20]

Data are presented as mean ± standard deviation or number [%]. pCR, pathologic complete response; IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.